Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease

Johann Wolfgang Goethe University Hospital572 enrolled

Overview

This study will evaluate the association of non-alcoholic fatty liver disease and coronary artery disease. All patients presenting for coronary angiogram will receive the following examination: * Transient Elastography and Controlled Attenuation Parameter using the FibroScan * blood examination including biochemical markers The results of non-invasive liver steatosis and fibrosis measurement are compared with the results of coronary angiogram concerning the presence or absence of coronary artery disease.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

572

Conditions

Nonalcoholic Steatohepatitis (NASH)

Interventions

Transient Elastography (FibroScan), Echosens, Paris, FranceDEVICE

Controlled Attenuation Parameter (CAP), Echosens, Paris, FranceDEVICE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female, 18 years and older * Written consent * Coronary angiogram planned Exclusion Criteria: * Patients with mental diseases * Pregnancy or lactation * Ascites

Locations (1)

Klinikum der J. W. Goethe-Universität

Frankfurt am Main, Germany

RECRUITING

Outcomes

Primary Outcomes

Liver fibrosis scores I-IV (METAVIR)

METAVIR fibrosis scores: I = mild fibrosis II = significant fibrosis III = advanced fibrosis IV = cirrhosis

Secondary Outcomes

Steatosis fibrosis scores I-III

Steatosis scores: 0 = \<5% I = 5-33% II = 33-66% III = \>66%

Central Contacts

Mireen Friedrich-Rust, MD

CONTACT

Mireen.Friedrich-Rust@kgu.de

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.